Detailed Technical Analysis:
Colgate-Palmolive India (COLPAL) trades at ₹2,106.70 (+0.8% close Jan 13) after strong intraday bounce from day low ₹2,088.90 (near 52-week low ₹2,033), showing classic oversold reversal with RSI(14) 19.96 (extreme oversold), STOCHRSI 0, Williams %R -94.9, and CCI -175 confirming exhaustion selling from multi-month downtrend. Pivot Points: Classic S1 ₹2,382/S2 ₹2,365/2,365/S3 ₹2,352 | R1 ₹2,412/R2 ₹2,425/R3 ₹2,442 – price holds above S3 support with bullish hammer candle and volume spike (288K vs avg 393K), targeting R1 ₹2,412 (14% upside) above ₹2,120 breakout trigger.
MACD(-32.56) divergence + ATR(12.72) contraction signals momentum shift; Strong Buy on hourly/daily oversold bounce amid FMCG defensive rotation, but failure below ₹2,088 risks S3 ₹2,352 retest.
Fundamental Analysis:
Q2FY26 Results (Oct 2025): Revenue ₹1,507 Cr (-6.3% YoY but +6.1% QoQ), PAT ₹328 Cr (-17% YoY) due to pricing pressure/gross margin contraction from 68% to 64.6%; EBITDA ₹482 Cr stable. TTM Metrics: Revenue ₹5,878 Cr (+6.33% YoY), Gross Profit ₹3,910 Cr (+23.91%), EBITDA ₹1,943 Cr (+7.1%), PAT ₹1,326 Cr (+8.55%), EPS ₹48.74, ROE 25-30%, debt-free balance sheet with strong cash flows. P/E ~55x (premium FMCG valuation), 3-yr sales CAGR 12%, dividend yield 2.1%; Q3FY26 expected Jan 22 with 5-7% revenue growth on volume recovery, but margin pressure from ad spends/raw materials persists. Strengths: #1 oral care share 52%, rural penetration; Risks: Competition from Patanjali/Dabur, pricing slowdown.
Important Events & Impact:
Q2FY26 Results (Oct 2025): PAT miss triggered 10% correction to 52-week lows, but oversold bounce underway.
Q3FY26 Results (Jan 22): Expected revenue ₹1,550-1,600 Cr (+3-6% QoQ), PAT ₹350 Cr – beat could spark 15% rally to ₹2,400+.
Wall Street Top Pick 2026: Morgan Stanley highlights organic sales reacceleration via emerging markets/oral care recovery.
Impact: Short-term volatility on results, long-term positive on global FMCG recovery narrative.
Micro & Macro View:
Micro: Strong Buy oversold bounce from ₹2,089 lows targeting ₹2,400-2,450 (R2); hold above ₹2,120 confirms, below ₹2,088 retest lows. Q3 catalyst key.
Macro: FMCG defensive play amid volatility; oral care ₹35,000 Cr market +8% CAGR, COLPAL 52% share leader. Global Colgate parent recovery + India rural push = structural upside to ₹3,000+.
Morning Rally Continuation?
Yes, strong continuation potential – subah ₹2,089 lows se +0.8% close ₹2,106.70 with volume confirmation and oversold indicators aligning perfectly; rally likely sustains above ₹2,120 targeting ₹2,250-2,400 if Q3 optimism builds, supported by hammer reversal and FMCG rotation – momentum intact!
Important News:
52-week low bounce: +4% from ₹2,033 (Dec 2025) to ₹2,106 amid market correction.
Morgan Stanley 2026 Top Pick: Sales growth reacceleration expected.
Q3 Preview (Jan 22): Analysts eye volume recovery post-pricing slowdown.
Margin pressure: Gross margin 64.6% vs 68% YoY due to input costs.
Disclaimer & Disclosure:
This analysis is purely educational and not investment advice. Past performance does not guarantee future results. Consult SEBI-registered financial advisor before any trading. Investogainer Research holds no position in COLPAL; data sourced publicly as of Jan 13, 2026. Risks include results volatility, raw material inflation, competition, and regulatory changes.